Ranjit Bindra is an Oncology physician affiliated with Yale New Haven Hospital. OpenAlex indexes 405 publications with 9,675 citations (h-index 44); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
20 York Street, Smilow Cancer Hospital, Yale New Haven
Lower Level
New Haven, CT 06510
Telephone
203-200-2100Registry record last updated 1 Mar 2016.
Clinical trials
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
Sponsor: Cavion, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20252 payments$20,583openpaymentsdata.cms.gov ↗
- Sage Therapeutics, LLCProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20243 payments$30,000openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
5 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Novel therapeutics for the targeted eradication of DDR-defective tumors
Yale University
FY2026$654,163R01CA276186 - Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML
Yale University
FY2026$585,107R01CA266604 - Novel therapeutics for the targeted eradication of DDR-defective tumors
Yale University
FY2025$654,163R01CA276186
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor
Molecular Cancer Therapeutics
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Sanacora, MD, PhD
Yale New Haven Hospital
John Elefteriades, MD
Yale New Haven Hospital
Jeptha Curtis, MD
Yale New Haven Hospital
Erica Spatz, MD
Yale New Haven Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”